Abstract:Objective This study sought to investgate the impact of high loading-dose atorvastatin pre-treatment in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) on coronary reperfusion, short-term clinical outcome and safety.Methods We collected consecutive patients with STEMI in our hospital from January 2010 to March 2011,83 patients who did not receive any statin therapy before admission and only received atorvastatin after admission were included. Patients were divided in 2 groups :those who received atorvastatin 80 mg before primary PCI (n=41) and those who did not (n=42).The primary end point included thrombolysis in myocardial infarction flow grade, corrected thrombolysis in myocardial infarction frame count, and myocardial blush grade after PCI. Secondary end point was 30-day incidence of MACE including cardiovascular death, nonfatal MI, and target vessel revascularization. The safety end point was the level of liver enzyme, creatine kinase and serum creatinine.Results Baseline clinical and procedural characteristics were similar between the 2 groups. The proportion of thrombolysis in myocardial infarction flow grade 3 was higher in the 80-mg atorvastatin arm(87.8% vs. 64.3%,χ2=6.28,P=0.02), and corrected thrombolysis in myocardial infarction frame count was also lower in the 80-mg atorvastatin arm (21.72±9.42 vs. 32.64±15.51, t=-3.87,P<0.001). Simultaneously, myocardial blush grade were higher in the 80 mg atorvastatin arm (2.71±0.64 vs.2.15±0.74,t=3.68,P<0.001). MACE occurred in 2 (4.9%) and 2 (4.8%) patients in the atorvastain 80 mg pre-treatment and control arm, respectively (χ2=0.001,P=0.926).There was not significant difference of liver enzyme, creatine kinase and serum creatinine between 2 groups. Multivariate analysis showed that high loading-dose atorvastatin pre-treatment was associated with an odds ratio of 0.22 (95% confidence interval 0.06 to 0.87, P=0.03) for slow reflow or no reflow after PCI.Conclusions High loading-dose atorvastatin pre-treatment may produce an optimal result for STEMI patients undergoing PCI by improving microvascular myocardial perfusion without increasing the risk of side-effect.

Pre-treatment of a single high-dose of atorvastatin provided cardioprotection in different ischaemia/reperfusion models via activating mitochondrial KATP channel

[Mechanisms of Cardioprotection Induced by Preconditioning after Activation of MITOK(ATP) Channel].

[The Protective Effect of Diazoxide on Long-Term Heart Preservation].

[Protective Effect of Mitochondrial ATP-sensitive Potassium Channel Opener on Rat Heart During Hypothermic Preservation].

Activation of Mitochondrial Atp-Sensitive Potassium Channel Contributes to Protective Effect in Prolonged Myocardial Preservation

Diazoxide Supplemented Celsior Solution Improves Hypothermic Heart Preservation Effect in Rat Through Activation of Mitochondrial ATP-sensitive Potassium Channel

Activation of Mitochondrial ATP-sensitive Potassium Channels Delays Ischemia-Induced Cellular Uncoupling in Rat Heart.

The Protective Effects of ATP-sensitive Potassium Channel Participating in Activation of Heme Oxygenase 1 (HO-1) on Ischemia-Reperfusion Injury in Heart

[Angiotensin-Converting Enzyme Inhibitors Potentiate Subthreshold Preconditioning Through NO and Mitok(atp) Channel.].

Cardioprotection of Ischemic Postconditioning Against Ischemia/reperfusion Injury in Isolated Rat Hearts

[Myocardial Protective Effect of Acetylcholine Against Ischemia/reperfusion Injury and Its Underlying Mechanism].

Short-Term Pretreatment with Atorvastatin Attenuates Left Ventricular Dysfunction, Reduces Infarct Size and Apoptosis in Acute Myocardial Infarction Rats

Involvement of the Mitochondrial Calcium Uniporter in Cardioprotection by Ischemic Preconditioning

Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia

Impact of high loading-dose atorvastatin pre-treatment before primary percutaneous coronary intervention on coronary flow in patients with ST segment elevation myocardial infarction

Inhibition of Mitochondrial Permeability Transition Pore: A Possible Mechanism for Cardioprotection Conferred by Pretreatment with Tanshinone IIA

β-hydroxybutyrate administered at reperfusion reduces infarct size and preserves cardiac function by improving mitochondrial function through autophagy in male mice

Oxytocin protects rat heart against ischemia–reperfusion injury via pathway involving mitochondrial ATP-dependent potassium channel

The Mitochondrial Ca2+-activated K+ Channel Contributes to Cardioprotection by Limb Remote Ischemic Preconditioning in Rat

Atractylenolide I Alleviates Ischemia/reperfusion Injury by Preserving Mitochondrial Function and Inhibiting Caspase-3 Activity

Ischemic Postconditioning Influences Electron Transport Chain Protein Turnover in Langendorff-perfused Rat Hearts